Trial Profile
An Open-Label, Randomized Efficacy and Safety Study of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary) ; Methotrexate
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms RESTORE1
- Sponsors Merck Sharp & Dohme
- 12 Sep 2011 Results published in the British Journal of Dermatology.
- 30 Sep 2009 New trial record.